Literature DB >> 18089699

Type I Gaucher disease, a glycosphingolipid storage disorder, is associated with insulin resistance.

Mirjam Langeveld1, Karen J M Ghauharali, Hans P Sauerwein, Mariette T Ackermans, Johanna E M Groener, Carla E M Hollak, Johannes M Aerts, Mireille J Serlie.   

Abstract

CONTEXT: Complex glycosphingolipids, in majority the ganglioside GM3, surround the insulin receptor in a special membrane compartment (raft) and modulate signaling through this receptor. Increased levels of GM3 in rafts impair insulin signaling, resulting in insulin resistance. Gaucher disease is a lysosomal storage disorder in which impaired breakdown of glucosylceramide leads to its accumulation in macrophages. Secondary to this defect, GM3 concentrations, for which glucosylceramide is the precursor, in plasma and several cell types are elevated.
OBJECTIVE: We studied the influence of glycosphingolipid storage on whole body glucose and fat metabolism by measuring insulin-mediated (IMGU) and noninsulin-mediated glucose uptake (NIMGU) and suppression of free fatty acids by insulin. DESIGN AND MAIN OUTCOME MEASURES: We studied six Gaucher patients, either naive to treatment or with considerable remaining burden of disease, and six matched healthy control subjects in the basal state, during an euglycemic and a hyperglycemic clamp with somatostatin measuring NIMGU and during an euglycemic hyperinsulinemic clamp measuring IMGU, using stable isotopes.
RESULTS: NIMGU (both during euglycemia and hyperglycemia) did not differ between patients and control subjects. IMGU was lower in Gaucher patients, compared with controls. Suppression of lipolysis by insulin tended to be less effective in Gaucher patients.
CONCLUSION: Gaucher disease, a lysosomal glycosphingolipid storage disorder, is associated with (peripheral) insulin resistance, possibly through the influence of glycosphingolipids on insulin receptor functioning.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18089699     DOI: 10.1210/jc.2007-1702

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  31 in total

1.  Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapy.

Authors:  John Marshall; Kerry Anne McEachern; Wei-Lien Chuang; Elizabeth Hutto; Craig S Siegel; James A Shayman; Greg A Grabowski; Ronald K Scheule; Diane P Copeland; Seng H Cheng
Journal:  J Inherit Metab Dis       Date:  2010-03-25       Impact factor: 4.982

Review 2.  How membrane dysfunction influences neuronal survival pathways in sphingolipid storage disorders.

Authors:  Tuba Sural-Fehr; Ernesto R Bongarzone
Journal:  J Neurosci Res       Date:  2016-11       Impact factor: 4.164

Review 3.  Glycosphingolipid functions.

Authors:  Clifford A Lingwood
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-07-01       Impact factor: 10.005

4.  A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1.

Authors:  Elena Lukina; Nora Watman; Elsa Avila Arreguin; Maryam Banikazemi; Marta Dragosky; Marcelo Iastrebner; Hanna Rosenbaum; Mici Phillips; Gregory M Pastores; Daniel I Rosenthal; Mathilde Kaper; Tejdip Singh; Ana Cristina Puga; Peter L Bonate; M Judith Peterschmitt
Journal:  Blood       Date:  2010-05-03       Impact factor: 22.113

5.  Regulation of human EGF receptor by lipids.

Authors:  Ünal Coskun; Michał Grzybek; David Drechsel; Kai Simons
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-13       Impact factor: 11.205

Review 6.  Ceramides as modulators of cellular and whole-body metabolism.

Authors:  Benjamin T Bikman; Scott A Summers
Journal:  J Clin Invest       Date:  2011-11-01       Impact factor: 14.808

7.  Life expectancy in Gaucher disease type 1.

Authors:  Neal J Weinreb; Patrick Deegan; Katherine A Kacena; Pramod Mistry; Gregory M Pastores; Priscilla Velentgas; Stephan vom Dahl
Journal:  Am J Hematol       Date:  2008-12       Impact factor: 10.047

8.  Insulin resistance in obesity can be reliably identified from fasting plasma insulin.

Authors:  K W ter Horst; P W Gilijamse; K E Koopman; B A de Weijer; M Brands; R S Kootte; J A Romijn; M T Ackermans; M Nieuwdorp; M R Soeters; M J Serlie
Journal:  Int J Obes (Lond)       Date:  2015-07-09       Impact factor: 5.095

Review 9.  Sphingolipids: the nexus between Gaucher disease and insulin resistance.

Authors:  Maria Fuller
Journal:  Lipids Health Dis       Date:  2010-10-11       Impact factor: 3.876

10.  Ganglioside GM3 levels are altered in a mouse model of HIBM: GM3 as a cellular marker of the disease.

Authors:  Thomas Paccalet; Zoé Coulombe; Jacques P Tremblay
Journal:  PLoS One       Date:  2010-04-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.